OpenURL Connection Search

Select item for more details and to access through your institution.

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
Published in:
Leukemia (08876924), 2014, v. 28, n. 7, p. 1501, doi. 10.1038/leu.2014.32
By:
- Beckwith, K A;
- Frissora, F W;
- Stefanovski, M R;
- Towns, W H;
- Cheney, C;
- Mo, X;
- Deckert, J;
- Croce, C M;
- Flynn, J M;
- Andritsos, L A;
- Jones, J A;
- Maddocks, K J;
- Lozanski, G;
- Byrd, J C;
- Muthusamy, N
Publication type:
Article
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.
Published in:
Leukemia (08876924), 2014, v. 28, n. 5, p. 1158, doi. 10.1038/leu.2014.9
By:
- Zhong, Y;
- El-Gamal, D;
- Dubovsky, J A;
- Beckwith, K A;
- Harrington, B K;
- Williams, K E;
- Goettl, V M;
- Jha, S;
- Mo, X;
- Jones, J A;
- Flynn, J M;
- Maddocks, K J;
- Andritsos, L A;
- McCauley, D;
- Shacham, S;
- Kauffman, M;
- Byrd, J C;
- Lapalombella, R
Publication type:
Article
Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND).
Published in:
Hematological Oncology, 2023, v. 41, p. 441, doi. 10.1002/hon.3164_325
By:
- Sehn, L. H.;
- Kuruvilla, J.;
- Salles, G.;
- Maddocks, K. J.;
- Koch, C.;
- Xue, Z.;
- Amoloja, T.;
- Amin, A.;
- Duell, J.
Publication type:
Article
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 439, doi. 10.1002/hon.3164_324
By:
- Duell, J.;
- Abrisqueta, P.;
- Dreyling, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.
Published in:
Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_323
By:
- Duell, J.;
- Abrisqueta, P.;
- Andre, M.;
- Augustin, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Kalakonda, N.;
- Liberati, A. M.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.72_2879
By:
- LaCasce, A. S.;
- Dockter, T.;
- Ruppert, A.;
- Kostakoglu, L.;
- Schöder, H.;
- Hsi, E. D.;
- Bogart, J. A.;
- Cheson, B. D.;
- Wagner‐Johnston, N. D.;
- Abramson, J. S.;
- Maddocks, K. J.;
- Leonard, J. P.;
- Bartlett, N. L.
Publication type:
Article
LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.28_2879
By:
- Duell, J;
- Maddocks, K. J;
- González‐Barca, E;
- Jurczak, W;
- Liberati, A. M;
- Obr, A;
- Gaidano, G;
- Abrisqueta, P;
- André, M;
- Dreyling, M;
- Menne, T;
- Dirnberger‐Hertweck, M.;
- Weirather, J;
- Ambarkhane, S;
- Salles, G
Publication type:
Article

Found: 7

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND).

Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma.

Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.

CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)

LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)